Loading
In 906 triple-negative patients from six German trials, half of the tumours with dense lymphocytes disappeared completely on chemotherapy before surgery against under a third of those with few, and more lymphocytes meant longer survival.
Pre-treatment core biopsies from 3,771 patients in six German Breast Group neoadjuvant trials were scored for stromal TILs by International TIL Working Group methods in three groups: low (0 to 10%), intermediate (11 to 59%) and high (60% or more). In TNBC, pCR was 31% (80 of 260) with low, 31% (117 of 373) with intermediate and 50% (136 of 273) with high TILs (P less than 0.0001); a 10% TIL increase was associated with longer disease-free survival (HR 0.93) and overall survival (HR 0.92). TILs predicted response in all subtypes but were an adverse survival factor in luminal-HER2-negative disease.
It fixes the lymphocyte-predominant share of TNBC at about 30% and shows TILs predict chemotherapy response before immunotherapy enters the picture.
Shares Carsten Denkert, Sibylle Loibl, German Breast Group (GBG), Pathologic complete response (pCR).
Shares Carsten Denkert, Sibylle Loibl, German Breast Group (GBG), Pathologic complete response (pCR).
Shares Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Carsten Denkert, Sibylle Loibl, German Breast Group (GBG), Pathologic complete response (pCR).
Shares Tumour-infiltrating lymphocytes (TILs), Pathologic complete response (pCR), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Pathologic complete response (pCR), Early triple-negative breast cancer, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Pathologic complete response (pCR), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).